Results for Novel, Glucocorticoid-Sparing Treatment for Patients with PMR

Overall, ABBV-154 was generally well tolerated with benefits observed vs. placebo. The study authors note that, due to early study termination, results should be interpreted with caution.

For complete details, including source material, refer to the full study.   

Excerpted and adapted from:

Spiera RF, Devauchelle-Pensec V, Owen CE, et al. Efficacy, safety, pharmacokinetics and immunogenicity of ABBV-154 in adults with glucocorticoid-dependent polymyalgia rheumatica: A phase 2, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2025 Aug;77(8):1041–1051.